RT Journal Article
T1 Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.
A1 García-Aranda, Marilina
A1 Téllez, Teresa
A1 McKenna, Lauraine
A1 Redondo, Maximino
K1 NK-1R
K1 cancer
K1 drug repurposing
K1 personalized medicine
K1 resistance
K1 tachykinin
K1 tachykinin receptor
K1 targeted treatment
AB Nowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare within sustainable health systems. Recent studies have demonstrated the role of Substance P (SP) and its preferred receptor, Neurokinin 1 Receptor (NK-1R), in human cancer and the potential antitumor activity of NK-1R antagonists as an anticancer treatment. In this review, we outline the relevant studies published to date regarding the SP/NK-1R complex as a key player in human cancer and also evaluate if the repurposing of already marketed NK-1R antagonists may be useful in the development of new treatment strategies to overcome cancer resistance.
SN 2072-6694
YR 2022
FD 2022-04-30
LK http://hdl.handle.net/10668/20890
UL http://hdl.handle.net/10668/20890
LA en
DS RISalud
RD Apr 19, 2025